Effects for Oral Mucositis Care During Chemoradiotherapy in Cancer Patients: Evaluation of the Bee Products

Sponsor
Taipei Medical University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05625841
Collaborator
(none)
135
1
3
25.2
5.4

Study Details

Study Description

Brief Summary

Oral mucositis is common among cancer patients receiving radiotherapy and chemotherapy. 80-90% of the patients are suffering from the mucositis pain; poor nutrition and even treatment discontinued. Some self-paid medications like glutamine has been used to prevent mucositis before and during radiotherapy/chemotherapy. Randomized controlled trials have shown that honey and propolis may be used for the management of mucositis. Honey demonstrates the most significant antibacterial effects; the green propolis has also been proved to comprise antibacterial, anti-inflammatory, and antioxidant effects. Bee products have been concerned as potential sources of natural antioxidants such as flavonoids, phenolic acids, and terpenoids. This study plan to conduct an RCT comparing the effectiveness of honey, honey and green propolis, and usual care in mucositis of cancer patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Honey product
  • Other: propolis
  • Other: Usual care
N/A

Detailed Description

Outcome Measures

  1. Questionnaire collection: oral mucositis grade, pain scale, fatigue scale, dry mouth, nutritional status and quality of life scale.

  2. Wearing the smart bracelet: The smart bracelet will automatically detect heart rate variability, heartbeat, sleep and activity status.

  3. Saliva sample collection: Test the concentration of IL-1, IL-6, IL-10 and TNF in saliva.

  4. Stool and oral flora collection: Test stool and oral flora microbiota.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
135 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Prevention and Improvement for Oral Mucositis Care During Chemoradiotherapy in Head and Neck Cancer Patients With Honey Production
Anticipated Study Start Date :
Nov 25, 2022
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Honey

Each pack of 10 grams of honey after three meals a day.

Other: Honey product
Bee products intervention from the first day of radiation to the end of radiation therapy duration 8-12 weeks.

Experimental: Honey and propolis

Each pack contains 0.7ml of propolis + 9.3g of honey after three meals a day.

Other: Honey product
Bee products intervention from the first day of radiation to the end of radiation therapy duration 8-12 weeks.

Other: propolis
propolis

Placebo Comparator: Usual care

General routine oral care.

Other: Usual care
Usual care

Outcome Measures

Primary Outcome Measures

  1. oral mucositis severity [up to 12 weeks]

    Ulceration or inflammation of the oral mucosa characterizes oral Mucositis

Secondary Outcome Measures

  1. pain score [up to 12 weeks]

    visual analogue score(VAS)

  2. fatigue level [up to 12 weeks]

    Brief Fatigue Inventory

  3. Xerostomia score [up to 12 weeks]

    Xerostomia Inventory

  4. nutrition level [up to 12 weeks]

    Mini Nutritional Assessment

  5. QoL questionnaire [up to 12 weeks]

    FACT-HN

  6. smart bracelet data [The first week, the fourth week, the 8th week start wearing the smart bracelet for 7 days]

    The smart bracelet will automatically detect heart rate variability, heartbeat, sleep and activity status

  7. Saliva specimen collection [This saliva is collected Baseline (before the start of radiotherapy), week 1, week 2, week 3, and up to 12 weeks]

    Test the concentration of IL-1, IL-6, IL-10 and TNF in saliva

  8. microbiota level [Baseline (Before the start of radiotherapy), week 2, week 4, and up to 12 weeks]

    Stool and oral flora collection

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. diagnosed with a head and neck tumor.

  2. receive chemotherapy or radiotherapy.

  3. conscious clear and willing to participate in the research.

  4. can communicate in Mandarin or Taiwanese.

Exclusion Criteria:

diabetes, arrhythmia, artificial heart rhythm device, allergic to bee products or alcohol.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Taipei Medical University Taipei Taiwan 110

Sponsors and Collaborators

  • Taipei Medical University

Investigators

  • Principal Investigator: Tsai-Wei Huang, PhD, Taipei Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Taipei Medical University
ClinicalTrials.gov Identifier:
NCT05625841
Other Study ID Numbers:
  • N2021100301
First Posted:
Nov 23, 2022
Last Update Posted:
Nov 23, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Taipei Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 23, 2022